CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB
D702AC00001
Phase 3 small_molecule active
Quick answer
CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB for HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active